more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Based in New Haven, CT, Alexion Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of life-transforming drugs, for the treatment of patients with ultra-rare disorders. The company’s complement franchise consists of key growth driver, Soliris, which is approved for the treatment of two severe and ultra-rare disorders resulting from chronic uncontrolled activation of the complement component of the immune system — paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Soliris is also approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. The FDA also approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of adult patients with PNH, to be administered every eight weeks. In October 2019, the FDA approved the use of Ultomiris as a treatment for adult and pediatric (one month of age or older) patients with aHUS to inhibit complement-mediated TMA.

Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU

by Zacks Equity Research Published on December 18,2019

The European Commission confers an orphan drug status on Dicerna's (DRNA) RNAi therapeutic DCR-A1AT for the treatment of congenital alpha-1 antitrypsin (A1AT) deficiency.

biotechs

Alexion Pharmaceuticals (ALXN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research Published on December 17,2019

Alexion Pharmaceuticals (ALXN) closed the most recent trading day at $109.82, moving -1.39% from the previous trading session.

ALXNPositive Net Change

3 Reasons Why Alexion (ALXN) Is a Great Growth Stock

by Zacks Equity Research Published on December 17,2019

Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.

ALXNPositive Net Change

Top Ranked Growth Stocks to Buy for December 16th

by Zacks Equity Research Published on December 16,2019

Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, December 16th

6 Low Price-to-Book Value Stocks to Buy in December

by Kinjel Shah Published on December 11,2019

P/B ratio is emerging as a convenient tool for identifying low-priced stocks with high-growth prospects.

Zacks.com featured highlights include: Quanta Services, Alexion Pharmaceuticals, Jazz Pharmaceuticals and Changyou.com

by Zacks Equity Research Published on December 10,2019

Zacks.com featured highlights include: Quanta Services, Alexion Pharmaceuticals, Jazz Pharmaceuticals and Changyou.com

medical

Alexion (ALXN) Looks Good: Stock Adds 6% in Session

by Zacks Equity Research Published on December 09,2019

Alexion (ALXN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

biotechs

Create a Standout Portfolio With These 4 Low P/CF Stocks

by Sumit Singh Published on December 09,2019

Investing in stocks based on value analysis is generally considered one of the best practices. In value investing, investors pick stocks that are usually cheap but fundamentally sound.

Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo

by Zacks Equity Research Published on December 06,2019

Zacks.com featured highlights include: Alexion Pharmaceuticals, OpGen, Integer, ReWalk Robotics and Civeo

5 Discounted PEG Stocks for GARP Investors

by Urmimala Biswas Published on December 05,2019

Although PEG is categorized under value investing, it follows the principles of both growth and value investing.

Adopt Rising P/E Technique With These 5 Top-Ranked Stocks

by Sanghamitra Saha Published on December 05,2019

What bargain hunting? Stocks with a rising P/E can also be worth buying too.

earnings

ALXN vs. ILMN: Which Stock Is the Better Value Option?

by Zacks Equity Research Published on December 04,2019

ALXN vs. ILMN: Which Stock Is the Better Value Option?

Biotech Stock Roundup: CBAY Falls, CCXI Gains, Amgen Acquires Otezla & More

by Zacks Equity Research Published on November 27,2019

Key highlights of the past week include regulatory and pipeline updates.

The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion

by Zacks Equity Research Published on November 27,2019

The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion

pharmaceuticals

4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal

by Kinjel Shah Published on November 26,2019

Here are four stocks that boast promising prospects and are most likely to be takeout targets.

Alexion Gets Approval for Label Expansion of Soliris in Japan

by Zacks Equity Research Published on November 25,2019

Alexion (ALXN) gets Japan Ministry of Health, Labour and Welfare's approval for the label expansion of Soliris.

biotechs

Alexion (ALXN) Up 3.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research Published on November 22,2019

Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ALXNPositive Net Change

The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals

by Zacks Equity Research Published on November 20,2019

The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals

medical

Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH

by Zacks Equity Research Published on November 20,2019

Achillion's (ACHN) lead pipeline candidate danicopan receives PRIME status from the EMA as a treatment option for PNH in patients, who are not adequately responding to a C5 inhibitor.